| Revision as of 18:47, 9 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 460517348 of page Technetium_(99mTc)_sulesomab for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 00:18, 25 January 2023 edit Entranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,412 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
|
{{DISPLAYTITLE:Technetium (<sup>99m</sup>Tc) sulesomab}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
| verifiedrevid = 447725939 |
|
| verifiedrevid = 470478372 |
|
| drug_name = Technetium (<sup>99m</sup>Tc) sulesomab |
|
| drug_name = Technetium (<sup>99m</sup>Tc) sulesomab |
|
⚫ |
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = Fab' |
|
| mab_type = Fab' |
|
| source = o |
|
| source = o |
|
| target = NCA-90 (granulocyte cell antigen) |
|
| target = NCA-90 (granulocyte cell antigen) |
|
⚫ |
<!-- Clinical data --> |
|
|
|
| ⚫ |
<!--Clinical data--> |
|
|
| tradename = |
|
| tradename = |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_status = Approved for use in Australia |
|
| legal_AU_comment= Approved |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
| metabolism = |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
| ⚫ |
<!--Identifiers--> |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
| CAS_number = 167747-19-5 |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
| ⚫ |
| CAS_number = <!-- blanked - oldvalue: 167747-19-5 --> |
|
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| CAS_supplemental = (unlabelled) |
|
|
|
| UNII = 709B6VM65P |
|
| ATC_prefix = V09 |
|
| ATC_prefix = V09 |
|
| ATC_suffix = HA04 |
|
| ATC_suffix = HA04 |
| Line 34: |
Line 32: |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = |
|
⚫ |
<!-- Chemical data --> |
|
|
|
| ⚫ |
<!--Chemical data--> |
|
|
| chemical_formula = |
|
| chemical_formula = |
|
|
|
|
| molecular_weight = |
|
| molecular_weight = |
|
}} |
|
}} |
|
|
'''Technetium (<sup>99m</sup>Tc) sulesomab''' (trade name '''LeukoScan''') is a radio-pharmaceutical composed of anti-human ] ]<ref>{{Cite web |url=http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list75.pdf |title=WHO Drug Information |access-date=2009-10-25 |archive-url=https://web.archive.org/web/20120219143028/http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list75.pdf |archive-date=2012-02-19 |url-status=dead }}</ref> that targets the granulocyte associated NCA-90 cell antigen and a conjugated ] ]. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by ] imaging of <sup>99m</sup>Tc-antibody bound cells.<ref>{{cite journal | vauthors = Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ | title = Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections | journal = Medical Principles and Practice | volume = 17 | issue = 6 | pages = 447–52 | date = 2008 | pmid = 18836272 | doi = 10.1159/000151565 | doi-access = free }}</ref> Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation<ref>{{cite journal | vauthors = Skehan SJ, White JF, Evans JW, Parry-Jones DR, Solanki CK, Ballinger JR, Chilvers ER, Peters AM | display-authors = 6 | title = Mechanism of accumulation of 99mTc-sulesomab in inflammation | journal = Journal of Nuclear Medicine | volume = 44 | issue = 1 | pages = 11–8 | date = January 2003 | pmid = 12515870 | url = http://jnm.snmjournals.org/content/44/1/11 | access-date = 2019-12-10 | archive-url = https://web.archive.org/web/20191210192401/http://jnm.snmjournals.org/content/44/1/11 | archive-date = 2019-12-10 | url-status = live }}</ref> |
|
|
|
|
|
It is approved in European markets for the imaging of ]s and ]s in patients with suspected ]<ref> {{Webarchive|url=https://web.archive.org/web/20061122113102/http://www.emea.europa.eu/humandocs/PDFs/EPAR/leukoscan/H-111-PI-en.pdf |date=2006-11-22 }}</ref><ref>{{cite journal | vauthors = Gratz S, Reize P, Kemke B, Kampen WU, Luster M, Höffken H | title = Targeting osteomyelitis with complete besilesomab and fragmented sulesomab antibodies: kinetic evaluations | journal = The Quarterly Journal of Nuclear Medicine and Molecular Imaging | volume = 60 | issue = 4 | pages = 413–23 | date = December 2016 | pmid = 25325395 }}</ref> but has not secured FDA approval for use in American markets.<ref>{{cite journal | vauthors = Vicente AG, Almoguera M, Alonso JC, Heffernan AJ, Gomez A, Contreras PI, Martin-Comin J | title = Diagnosis of orthopedic infection in clinical practice using Tc-99m sulesomab (antigranulocyte monoclonal antibody fragment Fab'2) | journal = Clinical Nuclear Medicine | volume = 29 | issue = 12 | pages = 781–5 | date = December 2004 | pmid = 15545877 | doi = 10.1097/00003072-200412000-00001 | s2cid = 46580717 }}</ref> In addition to approved uses, Leukoscan is currently being investigated for other diagnostic purposes like the detection of ] infections, malignant external otitis and prosthetic joint infection.<ref>{{cite journal | vauthors = Quigley AM, Gnanasegaran G, Buscombe JR, Hilson AJ | title = Technetium-99m-labelled sulesomab (LeukoScan) in the evaluation of soft tissue infections | journal = Medical Principles and Practice | volume = 17 | issue = 6 | pages = 447–52 | year = 2008 | pmid = 18836272 | doi = 10.1159/000151565 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Galletti F, Cammaroto G, Galletti B, Quartuccio N, Di Mauro F, Baldari S | title = Technetium-99m (<sup>99</sup>mTc)-labelled sulesomab in the management of malignant external otitis: is there any role? | journal = European Archives of Oto-Rhino-Laryngology | volume = 272 | issue = 6 | pages = 1377–82 | date = June 2015 | pmid = 24534898 | doi = 10.1007/s00405-014-2938-1 | s2cid = 25194736 }}</ref><ref>{{cite journal | vauthors = Iyengar KP, Vinjamuri S | title = Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections | journal = Nuclear Medicine Communications | volume = 26 | issue = 6 | pages = 489–96 | date = June 2005 | pmid = 15891591 | doi = 10.1097/00006231-200506000-00003 | s2cid = 41915486 }}</ref> However, the future clinical and investigational use of this agent may be limited as sale of the agent by the parent company ] was discontinued in 2018.<ref>{{Cite web|url=https://www.immunomedics.com/our-science/products/|title=Products|website=Immunomedics|language=en-US|access-date=2019-12-10|archive-url=https://web.archive.org/web/20191210192350/https://www.immunomedics.com/our-science/products/|archive-date=2019-12-10|url-status=live}}</ref> |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
== See also == |
|
|
* ] |
|
|
* ] |
|
|
|
|
|
{{Radiopharmaceuticals}} |
|
|
{{Monoclonals for immune system}} |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
|
|
|
|
|
|
{{monoclonal-antibody-stub}} |